Cargando…

Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

Peritoneal carcinomatosis (PC) from epithelial tumors is a fatal diagnosis without efficient treatment. Trifunctional antibodies (trAb) are novel therapeutic approaches leading to a concerted anti-tumor activity resulting in tumor cell destruction. In addition, preclinical data in mouse tumor models...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ströhlein, Michael A, Siegel, Robert, Jäger, Michael, Lindhofer, Horst, Jauch, Karl-Walter, Heiss, Markus M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644666/ https://www.ncbi.nlm.nih.gov/pubmed/19216794 http://dx.doi.org/10.1186/1756-9966-28-18

Ejemplares similares

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
por: Ruf, P, et al.
Publicado: (2007)

Potent CD4(+) T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
por: Deppisch, Nina, et al.
Publicado: (2016)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
por: Ruf, Peter, et al.
Publicado: (2021)

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model
por: Ruf, Peter, et al.
Publicado: (2012)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
por: Knödler, Maren, et al.
Publicado: (2018)

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors
por: Haense, N., et al.
Publicado: (2016)

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010)

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
por: Buhmann, Raymund, et al.
Publicado: (2013)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients
por: Ruf, Peter, et al.
Publicado: (2010)

Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis
por: Akce, Mehmet, et al.
Publicado: (2014)

Peritoneal carcinomatosis mimicking a peritoneal tuberculosis
por: Jung, Eun Young, et al.
Publicado: (2015)

CT mimics of peritoneal carcinomatosis
por: Smiti, S, et al.
Publicado: (2010)

An Unusual Case of Peritoneal Carcinomatosis
por: Hillewaere, Stijn, et al.
Publicado: (2010)

Lung cancer and peritoneal carcinomatosis
por: SERENO, MARÍA, et al.
Publicado: (2013)

Tuberculous peritonitis masquerading as carcinomatosis
por: Motoa, Gabriel, et al.
Publicado: (2020)

Splenosis Mimicking Peritoneal Carcinomatosis
por: Pichon, Louise, et al.
Publicado: (2020)

Peritoneal thickening: It's not always carcinomatosis
por: Sanae, Amalik, et al.
Publicado: (2021)

Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction
por: Alkhamesi, Nawar A., et al.
Publicado: (2007)

Alteration of Adaptive Immunity in a Colorectal Peritoneal Carcinomatosis Model
por: Shi, Rongchen, et al.
Publicado: (2019)

Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab(®))
por: Seimetz, Diane
Publicado: (2011)

Peritoneal Tuberculosis Mimicking Peritoneal Carcinomatosis in an Immunocompetent Patient
por: Abi El Hessen, Tony, et al.
Publicado: (2022)

Expansion microscopy with carboxylic trifunctional linkers: Expansion microscopy with carboxylic trifunctional linkers
por: Chen, Xuecheng, et al.
Publicado: (2022)

Hemangiopericytoma: an unusual cause of peritoneal carcinomatosis
por: Prakash, Mahesh, et al.
Publicado: (2009)

The treatment of peritoneal carcinomatosis in elderly patients
por: Macrì, A, et al.
Publicado: (2010)

Abdominal Sarcoidosis Mimicking Peritoneal Carcinomatosis
por: Roh, Won Seok, et al.
Publicado: (2018)

Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy
por: Kleber, Julia, et al.
Publicado: (2023)

Tumor Targeting, Trifunctional Dendritic Wedge
por: Dubey, Ramin, et al.
Publicado: (2014)

Peritoneal deciduosis mimicking peritoneal Carcinomatosis: A case report
por: Casanova, João, et al.
Publicado: (2021)

Clinical and Radiological Parameters to Discriminate Tuberculous Peritonitis and Peritoneal Carcinomatosis
por: Jha, Daya K., et al.
Publicado: (2023)

A Severe Case of Tuberculosis Radiologically and Endoscopically Mimicking Colorectal Cancer with Peritoneal Carcinomatosis
por: Rath, Timo, et al.
Publicado: (2017)

Peritoneal carcinomatosis mimicking a perforated diverticulitis
por: Facy, Olivier, et al.
Publicado: (2011)

Abdominal Sarcoidosis May Mimic Peritoneal Carcinomatosis
por: Gorkem, Umit, et al.
Publicado: (2015)

Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis in the Elderly
por: Spiliotis, J. D., et al.
Publicado: (2014)

Pathophysiology of colorectal peritoneal carcinomatosis: Role of the peritoneum
por: Lemoine, Lieselotte, et al.
Publicado: (2016)

Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
por: Simón-Gracia, Lorena, et al.
Publicado: (2018)

Hyaluronan-binding peptide for targeting peritoneal carcinomatosis
por: Ikemoto, Hideki, et al.
Publicado: (2017)

Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis
por: Nelson, Kirbylee K., et al.
Publicado: (2019)

Gastric peritoneal carcinomatosis - a retrospective review
por: Tan, Hwee Leong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_71jmftv7rrv3dutrt3keidhs4o